Biologics

Bioventus extended its agreement with Seikagaku Corp. to continue distributing Supartz Fx. Under the terms of this agreement, Bioventus will be Supartz Fx's exclusive distributor in the U.S. through May 2028.

Osiris selected Jason Keefer to serve as interim president and CEO.

U.S. Stem Cell reported a 106 percent revenue increase for the third quarter of 2017, reflecting a surging demand for stem cell treatments at its clinics.

Orthobiologics company Royal Biologics introduced Amnio-Maxx.

Regenerative medicine company Orthocell successfully conducted a pre-clinical evaluation using CelGro collagen rope for ACL reconstruction.

Medical device company CartiHeal secured a $2.5 million investment from Bioventus, bringing the latest financing round to $21 million. The funding will go to CartiHeal's ongoing Agili-C IDE clinical study.

The first cases of Triojection, a system intended to produce ozone gas for spinal disc herniations and manufactured by Minimus Spine, were performed in Germany by Thomas Vogl, MD.

Sacramento, Calif.-based Molecular Matrix received FDA 510(k) clearance for Osteo-P, a bone graft substitute technology.

Philadelphia-based University of Pennsylvania Health system researchers at the McKay Orthopaedic Research Laboratory are developing new tissue engineering approaches to improve treatment for meniscus tears, the most common form of orthopedic surgery.

Roger Hartl, MD, director of spinal surgery and neurotrauma at Weill Cornell Brain and Spine Center in New York City and director of the Weill Cornell Medicine Center for Comprehensive Spine Care, offers two key thoughts on where spine surgery…